PDT Partners LLC Takes $896,000 Position in RxSight, Inc. (NASDAQ:RXST)

PDT Partners LLC bought a new position in RxSight, Inc. (NASDAQ:RXST) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 18,129 shares of the company’s stock, valued at approximately $896,000.

Several other hedge funds also recently made changes to their positions in RXST. Walleye Capital LLC grew its holdings in RxSight by 620.2% in the 3rd quarter. Walleye Capital LLC now owns 129,687 shares of the company’s stock worth $6,410,000 after acquiring an additional 111,681 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in RxSight by 8.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,818 shares of the company’s stock valued at $3,402,000 after purchasing an additional 5,266 shares during the period. MetLife Investment Management LLC raised its position in RxSight by 4.0% during the 3rd quarter. MetLife Investment Management LLC now owns 20,525 shares of the company’s stock valued at $1,015,000 after purchasing an additional 790 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in RxSight by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,911 shares of the company’s stock worth $1,034,000 after buying an additional 399 shares during the period. Finally, Bank of Montreal Can grew its position in shares of RxSight by 32.4% in the 3rd quarter. Bank of Montreal Can now owns 119,580 shares of the company’s stock worth $5,804,000 after buying an additional 29,230 shares during the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Jesse Anderson Corley purchased 11,111 shares of RxSight stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $45.37 per share, for a total transaction of $504,106.07. Following the completion of the acquisition, the director now directly owns 468,571 shares of the company’s stock, valued at $21,259,066.27. The trade was a 2.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $53.19, for a total value of $164,889.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at approximately $2,247,064.74. This represents a 6.84 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,702 shares of company stock worth $3,059,197. Insiders own 9.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Jefferies Financial Group began coverage on RxSight in a report on Tuesday, October 29th. They set a “buy” rating and a $72.00 target price for the company. Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of RxSight in a research note on Friday, September 13th. Stifel Nicolaus decreased their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, Oppenheimer cut their price objective on RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $61.63.

RxSight Price Performance

NASDAQ:RXST opened at $46.88 on Monday. The firm has a market capitalization of $1.89 billion, a P/E ratio of -56.48 and a beta of 1.19. RxSight, Inc. has a one year low of $28.88 and a one year high of $66.54. The company’s 50-day simple moving average is $48.58 and its 200 day simple moving average is $52.26.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.